A phase I study of NK105 administrated weekly in patients with advanced solid malignancies.

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221196

Enrollment

Registered

2010-08-11

Start date

2010-08-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced solid malignancies

Interventions

investigational material(s) Generic name etc : NK105 INN of investigational material : Therapeutic category code : 424 Antineoplastic preparations extracted from plants Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically or cytologically confirmed malignant solid tumour. Refractory to standard therapy or for which no suitable effective standard therapy exists.

Exclusion criteria

Exclusion criteria: Treated with taxanes within 6 months

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Pharmacokinetics Efficacy	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026